Ocular FIP treatment enters a more evidence-based era
CURRENT BRIEF VERSION: Feline infectious peritonitis with ocular involvement is getting a more evidence-based treatment playbook, as new discussion in a VetGirl podcast points clinicians to emerging data on antiviral therapy, especially remdesivir and GS-441524, for cats with eye disease. The broader shift is that ocular FIP is no longer automatically viewed as a therapeutic dead end: retrospective and clinical reports now support meaningful survival with antiviral treatment, though cats with ocular or neurologic disease often need higher doses and closer follow-up than uncomplicated cases. The podcast also underscores a practical point for frontline clinicians: ocular FIP may be the first clue to systemic disease, with findings ranging from anterior uveitis, keratic precipitates, iris color change, dyscoria, hyphema, hypopyon, and fibrinous exudate to posterior segment lesions such as retinal hemorrhage, vascular tortuosity, retinal detachment, and perivascular cuffing. In the U.S., that conversation also lands differently than it did a few years ago, because veterinarians have been able to prescribe compounded GS-441524 for individual feline patients since June 2024 under FDA enforcement discretion, giving practices a more legitimate route than the gray-market options many pet parents previously relied on. (music.amazon.com)
Why it matters: For veterinary professionals, the practical takeaway is that ocular signs in suspected FIP should trigger urgency, not nihilism. Available guidance and published case series suggest these cats may require higher antiviral dosing because blood-ocular penetration can be a challenge as inflammation changes over time, and relapse risk may still warrant treatment adjustments or extended monitoring. It also means eye findings should not be dismissed as secondary detail: in some cats, uveitis or vision change is the dominant presentation, especially in non-effusive disease, where ocular and neurologic involvement are more common than in wet FIP. That makes client communication, access to quality-assured compounded product, and serial reassessment of ocular and systemic response especially important in general practice, ER, and referral settings. (cliniciansbrief.com)
What to watch: Watch for more protocol-specific data in ocular FIP, including whether shorter treatment courses can be used safely in these cats and how dose-escalation strategies affect relapse rates. (wormsandgermsblog.com)